The Question is from neet-botany biotechnology biotechnological-applications-in-medicine, and it was created by the author NISHANTH

Question

The development of biosimilars offers a cost-effective alternative to innovator biologics.  Which of the following is NOT a key characteristic that biosimilars must demonstrate compared to their reference product?

NISHANTH · Accepted Answer

## CORE INFORMATION
✓ **Answer**: C
## CONCEPT FRAMEWORK
 **Primary Concept**: Biosimilars and their characteristics
 **Related Topics**:  Pharmaceuticals, biologics, regulatory approval
 **Prerequisites**: Basic understanding of biologics and the drug development process.
## SOLUTION PATHWAY
**Given Information**:
  The question asks to identify a characteristic that biosimilars are *not* required to demonstrate in comparison to their reference product (the original biologic).
**Method & Steps**:
 1. Analyze each option to determine if it's a necessary characteristic of biosimilars.
  Reasoning: Biosimilars aim to be highly similar, but not identical, to their reference products.  They must meet stringent regulatory requirements demonstrating comparable safety and efficacy.
 2. Evaluate each option against the regulatory requirements for biosimilar approval.
  Working:  Let's examine each option:
        * **A (Highly similar physicochemical properties):** This is crucial. Biosimilars must have similar physical and chemical characteristics to the reference product.
        * **B (Comparable efficacy and safety profile):** This is a fundamental requirement. Extensive clinical trials demonstrate comparable efficacy and safety.
        * **C (Identical amino acid sequence):** This is NOT a requirement.  While high similarity is expected, minor variations in the amino acid sequence are often acceptable if they don't impact safety and efficacy.
        * **D (Similar pharmacokinetics and pharmacodynamics):** This is essential. Biosimilars must show similar absorption, distribution, metabolism, and excretion (pharmacokinetics) and similar effects on the body (pharmacodynamics).
 3. Identify the option that is NOT a necessary characteristic.
  Result: Option C (Identical amino acid sequence) is the correct answer because biosimilars don't need to have an identical amino acid sequence to their reference product.  They just need to be highly similar.
  Verification: Regulatory guidelines for biosimilars explicitly state that complete amino acid sequence identity isn't mandatory.
 ## OPTION ANALYSIS
A ✓: Highly similar physicochemical properties are a key characteristic of biosimilars.
B :x: Comparable efficacy and safety are essential for biosimilar approval.
C :x: Identical amino acid sequence is NOT required; high similarity is sufficient.
D :x: Similar pharmacokinetics and pharmacodynamics are crucial for biosimilar approval.
 ## LEARNING AIDS
 **Common Mistakes**:
  1.Confusing biosimilars with generic drugs: Biosimilars are complex biological molecules, unlike small-molecule generic drugs that must be chemically identical.
  2.Assuming complete identity is required:  This misunderstanding leads to selecting the incorrect option.
 **Quick Tips**:
  1.Focus on the regulatory requirements for biosimilar approval.
  2.Remember that biosimilars are highly similar, but not necessarily identical, to their reference products.

NISHANTH · Answer

Highly similar physicochemical properties

NISHANTH · Answer

Comparable efficacy and safety profile

NISHANTH · Answer

The correct Option is "Identical amino acid sequence"

NISHANTH · Answer

Similar pharmacokinetics and pharmacodynamics

NEET Botany Biotechnology and Its Applications Biotechnological Applications In Medicine MCQs

Select Topic

Question Tags

NEET Subjects

Our Bots

Company